药明合联荣获中国创新药十年荣耀榜“行业引领CDMO公司”
Swipe Left For English News 中国上海， 2025年9月29日 全球领先的生物偶联药物合同研究、开发和生产企业（CRDMO）药明合联（WuXi XDC，2268.HK）今日欣然宣布，其凭借卓越的服务质量、强大的技术实力、前瞻的全球化布局以及对产业创新的持续赋能，荣登“中国创新药十年荣耀榜”，并获评“行业引领CDMO公司”。本次获奖不仅是对药明合联在生物偶联药物CRDMO领域行业领导地位的认可，也是对其端到端的一站式专业能力和卓越服务的肯定。 “中国创新药十年荣耀榜”在第五届中国医药决策者峰会（2025 CHDC）上正式揭晓，该大会由北京医药健康科技发展中心和医药魔方联合主办。榜单以医药魔方全产业链数据为依托，榜下设8大荣誉奖项，旨在表彰过去十年取得优异成绩，同时为中国创新药产业升级发挥出推动与引领作用的优秀公司、机构和重大创新成果，为中国创新药产业的下一个十年确立标杆典范。其中，“行业引领CDMO公司”奖项是从CDMO公司对创新药产业的贡献力、业务竞争力等多维度进行综合评估，评选出以“价值服务”赋能中国医药创新、以“效率革命“助推中国创新药加速上市、重塑全球创新药竞争格局的标杆企业。 过去十年，中国创新药产业生态有了较大完善，产业链分工体系进一步成熟。包括药明合联在内的众多CDMO公司在过去十年征程中，通过高效、高质的服务，持续助推创新药批量上市，重塑了全球创新药的市场竞争格局。药明合联自成立以来，始终以“偶合天下药，联接健康梦”为愿景，为全球客户提供从早期发现到商业化生产的一站式解决方案。未来，药明合联将不断推进技术创新与服务平台迭代升级，与行业携手并进，释放生物偶联药更大的治疗潜力，构建更加开放、高效、共赢的创新生态，为医药产业的下一个黄金十年贡献核心支撑力量。 关于药明合联 （股票代码：2268.HK） 药明合联生物技术有限公司 (股票代码：2268.HK)是全球领先的生物偶联药合同研究、开发和生产企业(CRDMO)，公司为全球客户提供多样性的创新偶联技术及载荷连接子技术，助力新一代ADC研发，专注抗体偶联药物（ADC）及其他生物偶联药从早期研发、临床前到商业化生产的一站式服务，涵盖抗体或其他偶联药中间体、连接子/载荷连接子、偶联原液及偶联制剂等研发和GMP生产。 如需了解更多信息，请访问：www.wuxixdc.com 如需了解更多信息，敬请联系： 投资者关系：wuxixdc.ir@wuxibiologics.com 媒体问询：wuxixdc_pr@wuxibiologics.com 业务发展：wuxixdc_info@wuxibiologics.com WuXi XDC Named 'Industry Leading CDMO' at China Innovative Drug Decade Glory Awards Shanghai, China September 29, 2025 WuXi XDC Cayman Inc. ('WuXi XDC', stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that it has been awarded the 'Industry Leading CDMO' for its exceptional service quality, robust technological capabilities, global footprint, and continuous empowerment of industry innovation at the China Innovative Drug Decade Glory Awards. This recognition not only highlights WuXi XDC's industry-leading position but also affirms its end-to-end, integrated service capabilities. The China Innovative Drug Decade Glory Awards were presented at the 5th China Healthcare Decision-Makers Conference (2025 CHDC), co-hosted by Beijing Pharmaceutical Health Technology Development Center and Pharmcube. The Awards are based on the full industry chain data of Pharmacube and include eight major awards. It aims to recognize outstanding achievements over the past decade and to set examples for the next decade of the Chinese innovative drug industry by honoring excellent companies, institutions, and major innovative performance that have played a leading role in the upgrading of the Chinese innovative drug industry. Among them, the 'Industry Leading CDMO' award is comprehensively evaluated from multiple dimensions, including the contribution and business competitiveness of CDMO companies. It selects benchmark enterprises that empower Chinese pharmaceutical innovation with value-added services, promote the accelerated launch of Chinese innovative drugs with efficiency revolution, and reshape the global competitive landscape of innovative drugs. Over the past decade, China's innovative drug industry ecosystem has been significantly improved, and the division of labor within the industry chain has become more mature. Many CDMO companies, including WuXi XDC, have continuously promoted the mass launch of innovative drugs through efficient and high-quality services, reshaping the global competitive landscape of innovative drugs. Since our establishment, we have been committed to our vision of “Linking Innovation to Health”, providing global customers with integrated solutions from early discovery to commercial manufacturing. Moving forward, WuXi XDC will continue to enhance our technological innovation and service platforms, collaborate with industry partners, unlock the therapeutic potential of bioconjugates, build a more open, efficient, and win-win innovation ecosystem, and contribute to the next golden decade of the pharmaceutical industry. About WuXi XDC (stock code:2268.HK) WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com WuXi XDC Contacts Investor：wuxixdc.ir@wuxibiologics.com Media：wuxixdc_pr@wuxibiologics.com BD：wuxixdc_info@wuxibiologics.com
